A meta-analysis study which included 8 prospective randomized clinical trials (involved 4174 patients) with different form of cancer assessed the value of PD-L1 evaluation for predicting benefit from PD-1/PD-L1 (Shen and Zhao, 2018[56]). This evidence concerns the gene PDCD1 and cancer.